← Leaderboards
Ian E Krop
Dana-Farber Cancer Institute
$2,869,815
Attributed
$2,869,815
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $610.9K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,869,815 · 3
By mechanism
P50$1,652,991 · 1
P30$1,155,596 · 1
F32$61,228 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- Marcus W Bosenberg$17,371,466
- Gordon James Freeman$10,834,157
- William Y Kim$15,134,536
Others in their field
Top investigators on “Clinical Data”
- David Heimbrook · Leidos Biomedical Research, Inc.$880,833,027
- Leonard Freedman · Leidos Biomedical Research, Inc.$833,755,972
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$639,795,843
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$508,792,130
Research focus
Clinical DataCell CycleCollectionLaboratoriesClinical TrialsResearch PersonnelMinorityAgonistErbb2 GeneGenetically Engineered MouseEnvironmentBiopsy SpecimenBlood SpecimenBreast CarcinomaDesignCombination ImmunotherapyDrug ResistanceAntibodiesAnti-Tumor Immune ResponseCancer CenterCytotoxic ChemotherapyCdk4 GeneChemotherapyAnimal Experiments
Grant awards (9)
Clinical Protocol and Data Management$544,710
P30 · FY2025 · CA · contact PI
Clinical Protocol and Data Management$610,886
P30 · FY2024 · CA · contact PI
Project 2: Combination immunotherapy approaches to overcome therapeutic resistance in HER2-positive breast cancer$292,601
P50 · FY2023 · CA · contact PI
Project 2: Combination immunotherapy approaches to overcome therapeutic resistance in HER2-positive breast cancer$283,508
P50 · FY2022 · CA · contact PI
Project 2: Combination immunotherapy approaches to overcome therapeutic resistance in HER2-positive breast cancer$327,081
P50 · FY2021 · CA · contact PI
Project 2: Combination immunotherapy approaches to overcome therapeutic resistance in HER2-positive breast cancer$473,960
P50 · FY2020 · CA · contact PI
Project 2: Combination immunotherapy approaches to overcome therapeutic resistance in HER2-positive breast cancer$275,841
P50 · FY2019 · CA · contact PI
Characterization of HIN1 Putative Tumor Suppressor$15,668
F32 · FY2003 · CA
Characterization of HIN1 Putative Tumor Suppressor$45,560
F32 · FY2001 · CA